Drug updated on 11/1/2024
| Dosage Form | Injection (intravenous: 200 mg); Tablet (oral: 200 mg) |
| Drug Class | Oxazolidinone antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
Latest News
Summary
- This summary is based on the review of three systematic review(s)/meta-analysis(es). [1-3]
- For acute bacterial skin and skin structure infections (ABSSSI), tedizolid demonstrated effectiveness comparable to linezolid, showing no significant difference in therapeutic outcomes between the two treatments.
- Tedizolid exhibited strong in vitro efficacy against MRSA (methicillin-resistant Staphylococcus aureus) isolates, with a MIC(50) of 0.25 µg/mL and MIC(90) of 0.5 µg/mL, achieving 100% susceptibility (95% CI (confidence interval): 100-100) in MRSA samples.
- In treating pneumonia, tedizolid was significantly less effective than linezolid, indicating limited efficacy for this condition relative to alternative treatments.
- Tedizolid was associated with a lower incidence of gastrointestinal adverse events and blood/lymphatic system disorders compared to linezolid, and its safety profile is noted to be favorable, particularly for non-severe patients and in step-down therapy settings.
- In comparison to other treatments, linezolid presented a higher frequency of gastrointestinal adverse events and specific blood/lymphatic system disorders, including a dose-dependent decrease in platelet count.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Sivextro (tedizolid phosphate) Prescribing Information. | 2023 | Merck Sharp & Dohme LLC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis | 2024 | Antibiotics (Basel, Switzerland) |
| Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis | 2022 | Annals of Clinical Microbiology and Antimicrobials |
| Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM | 2022 | Biological & Pharmaceutical Bulletin |